These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6668547)

  • 1. Steady-state moxalactam pharmacokinetics in patients: noncompartmental versus two-compartmental analysis.
    Swanson DJ; Reitberg DP; Smith IL; Wels PB; Schentag JJ
    J Pharmacokinet Biopharm; 1983 Aug; 11(4):337-53. PubMed ID: 6668547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of moxalactam in patients with renal insufficiency.
    Lam M; Manion CV; Czerwinski AW
    Antimicrob Agents Chemother; 1981 Mar; 19(3):461-4. PubMed ID: 6454383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis.
    Albin H; Ragnaud JM; Demotes-Mainard F; Vincon G; Wone C
    Eur J Clin Pharmacol; 1986; 30(3):299-302. PubMed ID: 3732364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of moxalactam in elderly subjects.
    Andritz MH; Smith RP; Baltch AL; Griffin PE; Conroy JV; Sutphen N; Hammer MC
    Antimicrob Agents Chemother; 1984 Jan; 25(1):33-6. PubMed ID: 6703682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steady-state moxalactam kinetics: comparisons with other cephalosporins.
    Garzone P; Lyon J; Yu VL; Zuravleff J; Diven W; Pasculle W
    Clin Pharmacol Ther; 1981 Jul; 30(1):86-94. PubMed ID: 6453677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction.
    Bolton WK; Scheld WM; Spyker DA; Overby TL; Sande MA
    Antimicrob Agents Chemother; 1980 Dec; 18(6):933-8. PubMed ID: 6453555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latamoxef (moxalactam) kinetics in volunteers studied by a specific HPLC assay technique.
    Shepherd AM; Hardin TC; Ludden TM; Miner DJ; Coleman DL
    J Antimicrob Chemother; 1983 Oct; 12(4):377-86. PubMed ID: 6643333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of moxalactam in anuric children and during hemodialysis.
    Kaplan SL; Berry PL; Mason EO; Kramer WG
    Pediatr Pharmacol (New York); 1983; 3(1):29-36. PubMed ID: 6646877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of moxalactam in patients with normal and impaired renal function.
    Aronoff GR; Sloan RS; Luft FC
    J Infect Dis; 1982 Mar; 145(3):365-9. PubMed ID: 6460824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental pharmacokinetics of moxalactam.
    Reed MD; Aronoff SC; Myers CM; Husak MP; Bertino JS; Blumer JL
    Antimicrob Agents Chemother; 1983 Sep; 24(3):383-7. PubMed ID: 6638995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative pharmacokinetics of moxalactam and other cephalosporins].
    Fourtillan JB; Brisson AM
    Sem Hop; 1983 Jun; 59(26):1968-71. PubMed ID: 6310788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxalactam epimer kinetics in children.
    Nahata MC; Durrell DE; Barson WJ
    Clin Pharmacol Ther; 1982 Apr; 31(4):528-32. PubMed ID: 6460588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacokinetics of ceftazidime and moxalactam.
    Tjandramaga TB; Van Hecken A; Mullie A; Verbesselt R; De Schepper PJ; Verbist L
    Antimicrob Agents Chemother; 1982 Aug; 22(2):237-41. PubMed ID: 6765416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity, stability, and pharmacology of the epimers of moxalactam.
    Wise R; Wright N; Wills PJ
    Rev Infect Dis; 1982; 4 Suppl():S564-8. PubMed ID: 6218567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of dexrazoxane in subjects with impaired kidney function.
    Brier ME; Gaylor SK; McGovren JP; Glue P; Fang A; Aronoff GR
    J Clin Pharmacol; 2011 May; 51(5):731-8. PubMed ID: 20484616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate.
    Chládková J; Hak J; Martínková J; Chládek J
    Arzneimittelforschung; 2010; 60(12):769-75. PubMed ID: 21265469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of single-dose administration of moxalactam in unweaned calves.
    Soback S
    Am J Vet Res; 1989 Apr; 50(4):498-501. PubMed ID: 2653122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the pharmacokinetics and tissue penetration of ceftriaxone, moxalactam and cefotaxime.
    Wise R; Andrews JM
    Eur J Clin Microbiol; 1983 Oct; 2(5):505-8. PubMed ID: 6315427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay.
    Cheng JW; Charland SL; Shaw LM; Kobrin S; Goldfarb S; Stanek EJ; Spinler SA
    Pharmacotherapy; 1997; 17(3):584-90. PubMed ID: 9165563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the pharmacokinetics of latamoxef in normal and impaired renal function.
    Höffler D; Koeppe P; Moecke D
    Arzneimittelforschung; 1984; 34(3):317-20. PubMed ID: 6539614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.